ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 71

The Association Between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis-Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis

Ryan W. Gan1, Jan M. Hughes-Austin2, Kevin D. Deane3, Elaine M. Urbina4, Peter K. Gregersen5, Michael H. Weisman6, V. Michael Holers7 and Jill M. Norris1, 1Epidemiology, Colorado School of Public Health, Aurora, CO, 2Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Preventive Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 6Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 7Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose:  

Rheumatoid arthritis (RA) is characterized by systemic inflammation and immune dysregulation, including the presence of autoantibodies and elevated inflammatory markers in subjects with classifiable RA as well as in those who have yet to progress to clinically-apparent RA.  In addition, the risk for cardiovascular disease (CVD) is greatly increased in patients with RA, with autoantibodies and systemic inflammation believed to be major contributors to the pathogenesis of CVD in patients with RA.  Furthermore, Maradit-Kremers and colleagues have shown that the increased risk for CVD may precede the development of classifiable RA, leading to the hypothesis that autoantibodies and systemic inflammation are influencing the development of CVD in subjects even prior to the onset of joint symptoms in RA.  The Studies of the Etiology of RA (SERA) demonstrated previously an association between autoantibody positivity and increased levels of circulating cytokines in subjects without RA but at elevated risk for future RA, as they are first-degree relatives (FDRs) of probands with RA.  We utilized these SERA FDRs to test the hypothesis that CVD may be apparent in FDRs at-risk for future RA, and may also be related to systemic RA-related autoantibodies.

Methods:

RA-related autoantibody (Ab) positivity is defined as positivity for one of the following autoantibodies:  rheumatoid factor by nephelometry (RF), RF isotype-IgM, IgA, IgG, or anti-cyclic citrullinated peptide (anti-CCP2).  Ab positive and negative FDRs from the SERA parent cohort were evaluated after a 10-hour fast for the following outcome measures related to CVD: carotid intima media thickness (cIMT), carotid stiffness, flow-mediated dilation (FMD) of the brachial artery, abdominal adipose tissue using computed tomography (CT), blood pressure, lipids, lipoproteins and adipokines.  Levels of these pre-clinical CVD phenotypes were log-transformed and compared by current autoantibody positivity status using linear regression. 

Results:

The Table presents data from the first 30 FDRs undergoing the CVD evaluation (planned enrollment n=100).  Overall, Ab positive FDRs had lower (ie, better) intima media thickness of the internal carotid artery (both max and average measures) than Ab negative FDRs; there were no other significant differences between CVD-related measures and Ab status. 

Table:  CVD-related measures by RA-related autoantibody positivity.  CVD variables are back-transformed after adjusting for age and gender using linear regression.

Ab Positive  n=16

Mean

Ab Negative   n=14

Mean

p-value

Age (years)*

48.0

54.3

0.27

Gender (% Female)* †

81.3

57.1

0.24

Current Smoker (% Yes) * †

0%

14.3%

0.21

Blood Pressure

Systolic (mm/Hg)

118.79

118.16

0.92

Diastolic (mm/Hg)

72.99

72.91

0.98

Lipids, lipoproteins and adipokines

LDL (mg/dL)

98.39

114.92

0.27

HDL (mg/dL)

52.24

51.14

0.87

Cholesterol (mg/dL)

178.86

194.16

0.41

Triglycerides (mg/dL)

117.96

115.85

0.98

ApoB (mg/dL)

83.03

94.26

0.11

ApoA (mg/dL)

155.12

151.15

0.70

ApoB/ApoA

0.54

0.62

0.13

Adiponectin (ug/mL)

9.08

9.82

0.74

Leptin (ug/mL)

13.49

12.82

0.91

C-reactive protein (mg/L)

1.56

2.83

0.18

Adiposity

BMI (kg/m2)

28.70

27.47

0.63

Subcutaneous Fat Area (cm2) at L4/5

271.54

317.52

0.48

Visceral Fat (cm2) at L4/5

82.73

102.78

0.54

Carotid Intima Media Thickness (averaged over left and right cIMT)

cIMT, carotid bulb (max mm)

0.86

0.98

0.19

cIMT, carotid bulb (avg mm)

0.70

0.78

0.26

cIMT, common carotid artery (max mm)

0.72

0.75

0.50

cIMT, common carotid artery (avg mm)

0.59

0.63

0.34

cIMT, internal carotid artery (max mm)

0.65

0.81

0.02

cIMT, internal carotid artery (avg mm)

0.52

0.64

0.03

Measures of Carotid Stiffness

Peterson’s Elastic Model (mmHg)

525.39

524.63

0.99

Circumferential Arterial Strain (no units)

0.093

0.094

0.91

Beta Stiffness Index (no units)

5.59

5.60

0.99

Elastic Modulus, Incremental (mmHg)

2493.73

2381.08

0.88

Young’s Elastic Pressure Modulus (mmHg/mm)

466.90

455.57

0.94

Arterial Compliance (mm^2/mmHg)

0.103

0.103

0.99

Flow Mediated Dilatation (Δ%)

5.01

3.92

0.21

*Variables are unadjusted

† Variables are dichotomous and not log transformed.


Conclusion:

This preliminary analysis suggests that the autoantibody-positive FDRs did not have worse indicators of vascular health compared to autoantibody-negative FDRs, which is contrary to our a priori hypothesis.  These results tentatively indicate that the increased risk for CVD that is seen in RA is not detectable in the preclinical autoantibody phase of the disease, using the structural or functional vascular changes measured herein.  Analysis of the larger cohort is warranted to confirm these results.


Disclosure:

R. W. Gan,
None;

J. M. Hughes-Austin,
None;

K. D. Deane,
None;

E. M. Urbina,
None;

P. K. Gregersen,
None;

M. H. Weisman,
None;

V. M. Holers,
None;

J. M. Norris,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-preclinical-markers-for-cardiovascular-disease-and-rheumatoid-arthritis-related-autoantibodies-in-first-degree-relatives-without-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology